RXRX — Recursion Pharmaceuticals, Inc.

Is RXRX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of October 3, 2026

Recursion Pharmaceuticals, Inc. (RXRX) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $4.12. The rating moved from Neutral to Overbought on October 3, 2026.

See all overbought Healthcare stocks →

AI analysis

Recursion Pharmaceuticals, Inc. (RXRX) is an AI-enabled drug discovery company with a differentiated platform and a pipeline that offers upside via clinical readouts and partnership milestones. The company still exhibits typical clinical-stage biotech financials (negative cash flow and funding sensitivity), so near-term valuation is heavily dependent on capital markets access and platform validation events. Current market conditions—risk-off tone, a cooled IPO window and payer scrutiny—reduce investor appetite for high-volatility biotech stories and increase the likelihood of dilutive financings if runway is constrained. Positive clinical data, expanded collaborations, or clear platform commercialization evidence would materially improve prospects; conversely, clinical setbacks, slower partner uptake, or tighter reimbursement dynamics would weigh heavily on shares.

Key factors

  • Proprietary AI-driven drug discovery platform that can accelerate target identification and de-risk early programs
  • Broad preclinical / early-clinical pipeline and multiple collaborations/licensing relationships that provide optionality and non-dilutive milestones
  • High cash burn typical of clinical-stage biotech; balance-sheet and runway dynamics will drive near-term funding events and share volatility
  • Current macro risk-off tone, cooled healthcare IPO window and light volumes reduce appetite for high-volatility biotech financings
  • Regulatory and payer environment (Medicare drug-price negotiation) raising long-term pricing pressure for certain novel therapeutics
  • Platform validation milestones (positive clinical readouts or partnership expansions) would be key near-term catalysts

Risks

  • Limited near-term revenue and continued negative free cash flow requiring equity raises or partnering that could dilute existing holders
  • Clinical trial failures or ambiguous readouts that would materially reduce valuation for early-stage programs
  • Platform risk: failure to consistently translate AI/biology discoveries into clinically meaningful assets
  • Downward pricing / access pressure from policy actions (IRA and other payer dynamics) that could compress future commercial upside
  • Increased competition from larger pharma, specialized biotech and other AI-driven discovery firms
  • Market liquidity risk and high sensitivity to macro risk-off environments that can widen bid-ask spreads and amplify short-term declines

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for RXRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.